ARK Reports 8.36% Of Recursion's Class A Shares And Certifies A Passive Purpose

The investment manager's September 30 position covered 44,745,024 shares in the AI drug developer.

Share
ARK Reports 8.36% Of Recursion's Class A Shares And Certifies A Passive Purpose

ARK Investment Management reported an 8.36% stake in Recursion Pharmaceuticals, which uses artificial intelligence and automated labs to develop medicines, in an SEC passive ownership filing Friday. The position covered 44,745,024 Class A shares as of September 30, and ARK certified that its holdings were not intended to influence company control.

ARK And Wood's Voting Authority

ARK reported sole authority to vote 42,796,887 shares, with another 548,854 shares under shared voting authority.

Catherine D. Wood, ARK's chief executive and chief investment officer, was a joint reporting person. Her reported shared voting authority covered 43,345,741 shares. ARK and Wood reported the same 44,745,024-share beneficial-ownership position; those entries describe the same holdings, not separate stakes to add together.

The passive certification says the securities were bought and held as part of ordinary business, without a purpose or effect of changing Recursion's control.

An AI Drug-Discovery Holding

Recursion's business combines biological data generation, small-molecule design and clinical trial work through its Recursion Operating System. Its automated laboratories can conduct more than 2 million experiments a week, according to its annual report for the fiscal year ended December 31, 2025.

That report described five clinical programs and two preclinical programs spanning oncology and rare disease. Among them is REC-4881 for familial adenomatous polyposis.

Recursion also conducts partner-funded discovery work in oncology, neuroscience and immunology with Roche and Genentech, Sanofi, Bayer and Merck KGaA. It had received more than $500 million in upfront and milestone payments from partners to date, according to the annual report.

ARK's exchange-traded funds hold concentrated positions in small- and mid-cap companies, frequently taking its ownership above the 5% disclosure threshold. The manager has produced roughly 170 ownership schedules over two years.

Recursion's market capitalization was $2.1 billion in Friday trading as of 12:51 p.m. ET.

The ownership report measures ARK's September 30 position; Friday was the filing date.

Sources

More on Recursion Pharmaceuticals

All Recursion Pharmaceuticals (RXRX) coverage →